3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
fludarabine phosphate
4
fludarabine
4
Cyclophosphamide
4
Thiotepa
3
Melphalan
3
Whole-Body Irradiation
2
Tacrolimus
2
Surveys and Questionnaires
2
Fentanyl
2
Busulfan
2
Alemtuzumab
2
AP 1903 reagent
2
voxelotor
1
thymoglobulin
1
maltodextrin
1
Rituximab
1
Registries
1
Range of Motion, Articular
1
Protease Inhibitors
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Medical Marijuana
1
Interviews as Topic
1
Imagery, Psychotherapy
1
Holistic Health
1
Glutamine
1
Erythrocyte Count
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anemia, Sickle Cell
×
Medical Marijuana
×
Classical hematology
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled